XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34(+)38(−) cells in a phase 1/2 study of patients with relapsed/refractory AML

XIAP, a potent caspase inhibitor, is highly expressed in acute myeloid leukemia (AML) cells and contributes to chemoresistance. A multi-center phase 1/2 trial of XIAP antisense oligonucleotide AEG35156 in combination with idarubicin/cytarabine was conducted in 56 patients with relapsed/refractory AM...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Carter, Bing Z., Mak, Duncan H., Morris, Stephen J., Borthakur, Gautam, Estey, Elihu, Byrd, Anna L., Konopleva, Marina, Kantarjian, Hagop, Andreeff, Michael
Formato: Artigo
Idioma:Inglês
Publicado: 2011
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3376026/
https://ncbi.nlm.nih.gov/pubmed/20938744
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10495-010-0545-1
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares